EUVIMEDOpdag EUVIMED
Crossref

A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies

Feyzi Sinan Tokalı iD, Halil Şenol iD, Şeyma Ateşoğlu iD, Fahri Akbaş iD

Chemical Biology & Drug Design · 2024-07 · 104 (1)

DOI: 10.1111/cbdd.14599 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2024-07-22. Written by Feyzi Sinan Tokalı and 3 co-authors. Institution: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey. Major MEDLINE topics: Molecular Docking Simulation, Molecular Dynamics Simulation, Antineoplastic Agents, Lung Neoplasms. Cited 46 times so far (Crossref); 36 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

In this study, we synthesized 15 novel quinazoline‐morpholinobenzylideneamino hybrid compounds from methyl anthranilate and we assessed their cytotoxicity via in vitro assays against A549 and BEAS‐2B cell lines. Molecular docking studies were conducted to evaluate the protein‐ligand interactions and inhibition mechanisms on nine different molecular targets, while molecular dynamics (MD) simulations were carried out to assess the stability of the best docked ligand–protein complexes. Additionally, ADME prediction was carried out to determine physicochemical parameters and drug likeness. According to the cytotoxicity assays, compound 1 (IC 50 = 2.83 μM) was found to be the most active inhibitor against A549 cells. While the selectivity index (SI) of compound 1 is 29, the SI of the reference drugs paclitaxel and sorafenib, used in this study, are 2.40 and 4.92, respectively. Among the hybrid compounds, 1 has the best docking scores against VEGFR1 (−11.744 kcal/mol), VEGFR2 (−12.407 kcal/mol) and EGFR (−10.359 kcal/mol). During MD simulations, compound 1 consistently exhibited strong hydrogen bond interactions with the active sites of VEGFR1 and 2, and these interactions were maintained for more than 90% of the simulation time. Additionally, the RMSD and RMSF values of the ligand–protein complexes exhibited high stability at their minimum levels around 1–2 Å. In conclusion, these findings suggest that compound 1 may be a potent and selective inhibitor candidate for lung cancer treatment and inhibition of VEGFR2, especially.

Subjects

MeSH terms (MEDLINE)

Molecular Docking SimulationMolecular Dynamics SimulationAntineoplastic AgentsLung NeoplasmsMorpholinesHumansCell Line, TumorErbB ReceptorsA549 CellsQuinazolinonesVascular Endothelial Growth Factor Receptor-2QuinazolinesBinding SitesDrug Screening Assays, AntitumorHydrogen Bonding

Author keywords

cytotoxicityin silicolung cancermorpholinobenzylidenequinazoline‐4(3H)‐one

Substances

Antineoplastic AgentsMorpholinesErbB ReceptorsQuinazolinonesVascular Endothelial Growth Factor Receptor-2Quinazolines

Authors and institutions

  • Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.
  • Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
  • Department of Biotechnology, Institute of Health Sciences, Bezmialem Vakif University, Istanbul, Turkey.

ORCID profiles: Feyzi Sinan Tokalı, Halil Şenol, Şeyma Ateşoğlu, Fahri Akbaş

Cite

APA

Tokalı, F. S., Şenol, H., Ateşoğlu, Ş., & Akbaş, F. (2024). A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Chemical Biology & Drug Design, 104(1). https://doi.org/10.1111/cbdd.14599

Vancouver

Tokalı FS, Şenol H, Ateşoğlu Ş, Akbaş F. A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Chemical Biology & Drug Design. 2024;104(1). doi:10.1111/cbdd.14599

BibTeX
@article{Tokal2024,
  author = {Tokalı, Feyzi Sinan and Şenol, Halil and Ateşoğlu, Şeyma and Akbaş, Fahri},
  title = {A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies},
  journal = {Chemical Biology & Drug Design},
  year = {2024},
  volume = {104},
  number = {1},
  doi = {10.1111/cbdd.14599}
}
Start for free →